Anaphylaxis and serum sickness in patients receiving omalizumab: Reviewing the data in light of clinical experience

Annals of Allergy, Asthma and Immunology

Volumn 115, Issue 1, 2015, Pages 77-78

  Harrison, Rachel G ^a   Macrae, Megan ^a   Karsh, Jacob ^b   Santucci, Stephanie ^a   Yang, William H ^a,b  

^a Ottawa Allergy Research Corporation   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC ASTHMA; ANAPHYLAXIS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; SERUM SICKNESS; TREATMENT DURATION; TREATMENT OUTCOME; CANADA; CHEMICALLY INDUCED; DRUG HYPERSENSITIVITY; DRUG LABELING; POSTMARKETING SURVEILLANCE; PREVALENCE; UNITED STATES;

ANAPHYLAXIS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CANADA; DRUG HYPERSENSITIVITY; DRUG LABELING; HUMANS; PREVALENCE; PRODUCT SURVEILLANCE, POSTMARKETING; SERUM SICKNESS; UNITED STATES;

EID: 84937515197     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2015.04.014     Document Type: Article

References (10)

1. S. Holgate, T. Casale, S. Wenzel, J. Bousquet, Y. Deniz, and C. Reisner The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation J Allergy Clin Immunol 115 2005 459 465
2. Novartis, Inc. Xolair (omalizumab) [product insert]. Dorval, Quebec, Canada; 2011.
3. US Food and Drug Administration Center for Biologics Evaluation and Research. BLA STN 103976/0, briefing document on safety (Genentech Inc) 2003 Department of Health and Human Services Rockville, MD
4. C. Pilette, N. Coppens, F.A. Houssiau, and D.O. Rodenstein Severe serum sickness-like syndrome after omalizumab therapy for asthma J Allergy Clin Immunol 120 2007 972 973
5. D.H. Dreyfus, and C.C. Randolph Characterization of an anaphylactoid reaction to omalizumab Ann Allergy Asthma Immunol 96 2006 624 627
6. US Food and Drug Administration. FDA proposes to strengthen label warning for Xolair [news release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108850.htm. Published 2007. Accessed February 17, 2015.
7. L. Cox, T.A.E. Platts-Mills, I. Finegold, L.B. Schwartz, E.R. Simons, and D.V. Wallace American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis J Allergy Clin Immunol 120 2007 1373 1377
8. L. Cox, P. Lieberman, D. Wallace, and et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report J Allergy Clin Immunol 128 2011 210 212
9. Z.W. Birnbaum, and M.G. Sirken Design of sample surveys to estimate the prevalence of rare diseases: three unbiased estimates Vital Health Stat 2 11 1965 1 8
10. Committee for Orphan Medicinal Products. Points to consider on the calculation and reporting of the prevalence of a condition for orphan designation. European Agency for the Evaluation of Medicinal Products. COMP/436/01. www.ema.europa.eu/ema/pages/includes/document/open-document.jsp?webContentId=WC500003773. Published March 26, 2002.